Industry News

The Office for Life Sciences (OLS) is a joint unit between the Department of Health & Social Care (DHSC) and the Department for Business, Energy & Industrial Strategy (BEIS). Medilink shares this bulletin with its members and networks to keep the life sciences sector up to date on the latest guidance as we approach the end of […]

The UK will join the USA, Canada, Australia, Switzerland, Singapore and Brazil to speed up the approval of innovative medicines. International regulators will work together to authorise promising treatments after the EU transition period Medicines will include cancer treatments NHS patients could have quicker access to the next generation of cutting-edge treatments thanks to the […]

This week’s OLS Bulletin includes MHRA’s published, first formal regulatory guidance on the post-transition period. This included guidance on Clinical trials, Medical Devices, Licensing, Importing and exporting, IT systems, Pharmacovigilance, and Paediatrics

Medilink shares this bulletin with its members and networks, aimed to keep the life sciences sector up to date on the latest guidance whilst the UK is in the transition period and during the Coronavirus (COVID-19) outbreak.

Medilink shares this bulletin with its members and networks, aimed to keep the life sciences sector up to date on the latest guidance whilst the UK is in the transition period and during the Coronavirus (COVID-19) outbreak.

Medilink shares this bulletin with its members and networks, aimed to keep the life sciences sector up to date on the latest guidance whilst the UK is in the transition period and during the Coronavirus (COVID-19) outbreak.

Medilink WM brings you the latest updates from the Office for Life Sciences.

Medilink shares this bulletin with its members and networks, aimed to keep the life sciences sector up to date on the latest guidance whilst the UK is in the transition period and during the Coronavirus (COVID-19) outbreak.

Medilink WM brings you the latest updates from MHRA in this week’s OLS Bulletin.

Collated guidance for business on no deal preparations, including update on ‘Continued Supply of Medical Devices and Clinical Consumables’ and ‘MHRA Guidance and Publications on a Possible No Deal Scenario’.